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Abstract:
To assess the feasibility of using sandwich cultured human hepatocytes (SCHH) as a model for characterizing transport kinetics for in vivo pharmacokinetic prediction, the expression of OATP proteins in SCHH, along with biliary efflux transporters ), were quantitatively confirmed by LC-MS/MS. Rifamycin SV (Rif SV), which was shown to completely block the function of OATP transporters, was selected as an inhibitor for assessing the initial rates of active uptake. The optimized SCHH model was applied in a retrospective investigation of compounds with known clinically significant OATP-mediated uptake and was further applied to explore drug-drug interactions (DDIs).
Greater than 50% inhibition of active uptake by Rif SV was found to be associated with clinically significant OATP-mediated DDIs. We propose that the in vitro active uptake value could therefore serve as a cutoff for class 3 and 4 compounds of biopharmaceutics drug disposition classification system (BDDCS), which could be integrated into the International Transporter Consortium (ITC) decision tree recommendations (Giacomini et al., 2010) to trigger clinical evaluations for potential DDI risks. Furthermore, kinetics of in vitro hepatobiliary transport obtained from SCHH, along with protein expression scaling factors, offer an opportunity to predict complex in vivo processes using mathematical models, such as physiologically-based pharmacokinetics models (PBPK).
Introduction
Hepatobiliary elimination are primary elimination routes for many endogenous and exogenous xenobiotics. Hepatic uptake and efflux transporters respectively located on sinusoidal or canalicular membranes, contribute to the vectorial transport of drugs and their metabolites from systemic circulation to bile (Meier et al., 1997; Kullak-Ublick et al., 2000) . Two classes of hepatic uptake transporters, sodium-dependent and sodiumindependent transporters, co-exist on the sinusoidal membrane of hepatocytes with overlapping substrate specificities. For example, the sodium-dependent transporter, sodium-taurocholate co-transporting polypeptide (NTCP), is shown to transport the organic anion transporting polypeptide (OATP) substrates atorvastatin and rosuvastatin (Ho et al., 2006; Choi et al., 2011) . OATP1B1/1B3, organic anion transporter 2 (OAT2) and organic cation transporter 1 (OCT1) are specifically expressed in the liver and transport structurally diverse substrates in a sodium-independent manner. In the last decade, significant advances toward the prediction of in vivo NME clearance using in vitro models have been well-documented. Indeed, in vitro human liver microsomes and isolated hepatocytes were shown to be important tools in drug discovery and development to confidently predict in vivo human drug metabolism for compounds DMD #43489
predominately eliminated by cytochrome P-450 (Obach, 1999; McGinnity et al., 2004) .
However, human PK prediction remains very challenging for compounds where drug transporters are involved in the clearance mechanism. In 2010, the International Transporter Consortium (ITC) recommended decision trees using in vitro systems to assess the risk of in vivo transporter mediated drug-drug interactions (DDIs) (Giacomini et al., 2010) . For OATP transporters, the investigation cascade is initiated by the criteria of active hepatic uptake if hepatic clearance is an important route of elimination, e.g >0.3
of total clearance (Giacomini et al., 2010) . However, the models and the extent of active hepatic uptake that would trigger the investigation cascade remain undetermined and suitable in vitro tools to assess the active/passive hepatic uptake need to be further validated. We hypothesized that clinically relevant OATP mediated DDI is associated with significant active uptake in vitro.
Recently, a physiologically-based pharmacokinetic (PBPK) model, in which physiological compartments representing organs/tissues are connected with blood flow, was developed to predict in vivo clearance and time profiles of drug elimination using in vitro models such as suspension hepatocytes and canalicular membrane vesicles (Watanabe et al., 2009 tissue concentration, drug-drug interaction, and the effects of enzyme/transporter genetic polymorphisms on drug exposure. Practically, parameters for distinct clearance processes including passive diffusion, transporter-mediated hepatic uptake (sinusoidal), metabolism, and transporter-mediated efflux (canalicular) into the bile could be determined in vitro and used to predict in vivo human.
The sandwich cultured hepatocyte model (SCH) built by culturing hepatocytes between two layers of gelled matrix in a sandwich configuration, forms a bile canalicular network and provides the three-dimensional orientation and proper localization of hepatobiliary transporters that mimic in vivo conditions and allow the vectorial transport of xenobiotics (Bi et al., 2006) . In 2006, Turncliff et al. evaluated the hepatobiliary disposition of metabolites of terfenadine generated in sandwich cultured rat hepatocytes (SCRH) (Turncliff et al., 2006) . The advancement of in vitro models for the clearance prediction in human has further reflected an increase in the mechanistic understanding of the hepatic vectorial elimination process (Kotani et al., 2011) . For example, by using LC-MS/MS quantification methods, the expression of biliary efflux transporters in sandwich cultured rat hepatocytes (SCRH) were determined and used to improve the extrapolation from in vitro to in vivo for the compounds excreted from bile Li et al., 2010 
Sandwich cultured human hepatocytes (SCHH)
Cryopreserved hepatocytes were thawed and plated as described previously (Bi et al., 2006) . In brief, hepatocytes were thawed in a water bath at 37°C, and then immediately poured into 50 mL in pre-warmed In Vitro GRO-HT medium in a conical 
Extraction and digestion of membrane protein
At day 5 post culture, SCHH were detached from cell culture plates and washed with HBSS. Along with suspension hepatocytes, the membrane protein fraction of hepatocytes was extracted as described previously (Li et al., 2008) (Li et al., 2008) . LC-MS quantification for human OATP proteins and two of six peptides identified (NVTGFFQSFK and SSPAVEQQLLVSGPGK) were also reported by Ji et al (Ji et al., 2012) . The digestion condition were optimized by our previous report (Balogh et al., 2012) . Briefly, 80 μg of membrane fraction protein was reduced with 6 mM dithiothreitol and alkylated with iodoacetamide in 25 mM ammonium bicarbonate digestion buffer containing 10% sodium deoxycholate monohydrate (DOC), and then digested by trypsin (the final concentration of DOC during digestion was 1%). At the end of digestion, samples were acidified with an equal amount of 0.2% formic acid in water with SIL internal standards, and centrifuged at 14,000 x g for 5 minutes. The supernatants were transferred to a new plate and dried down. The samples were reconstituted with 0.1% formic acid in water and analyzed by LC-MS/MS.
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The calibration curve was prepared using the synthetic proteotypic peptide with a fixed concentration of each SIL peptide as the internal standard. (Table 1) . Data were processed by integrating the appropriate peak areas for the analyte peptides and the SIL internal standard peptides in Analyst 1.4.2 (Applied Biosystems, Foster City, CA).
Determination of hepatic uptake in SCHH
SCHH were rinsed twice with 0. rosuvastatin uptake in SCHH, parallel incubations were conducted in the presence of the uptake transporter inhibitors, Rif SV (100 μΜ), Cyclosporin A (CsA, 10 μΜ), and gemfibrozil (30 μΜ). SCHH uptake was initiated by the addition of 500 µL containing substrate at a concentration indicated in the figure legends, with or without inhibitors.
Reactions were terminated at designated time points by quickly washing the hepatocytes three times with ice-cold HBSS buffer. The cells were either lysed with 0.5% Triton-100 (radiolabeled compounds) or 100% methanol containing internal standard (nonradiolabeled compounds). Samples were analyzed either by LC-MS/MS, respectively. 
LC-MS/MS Analysis of Probe Substrates
LC-MS/MS
Data Analysis
The apparent in vitro biliary clearance (CL bile ) (Liu et al., 1999) and percent active uptake were determined by equations 1 and 2, respectively. The hepatic uptake of test compounds was estimated from the initial uptake phase (0.5 to 1 min) while biliary excretion was assessed at 10 minutes. The data represent the results from a single study run in triplicate or duplicate and a minimum of two experiments were performed. The standard deviations or coefficient variation (CV%) was listed in the legends of figure or 
Results
Protein expression of OATP1B1, 1B3, and 2B1 in suspension hepatocytes and SCHH
As functional active uptake has been shown previously in SCHH both in house and in the literature (Kotani et al., 2011) , in the present study, the protein expression of OATP1B1, 1B3, and 2B1 in SCHH was measured by LC-MS/MS and compared with that in suspension hepatocytes. Peptides proteolytically released from the target OATP proteins were quantified using external synthetic peptide calibration curves. The peptide fragments were monitored using multiple reactions monitoring (MRM) ( Table 1) . Sample preparation, digestion, and detection limits of OATP protein quantification were previously evaluated (Balogh et al., 2012) . As shown in Table 2 , while OATP1B3 and 2B1 expression levels were reduced to approximately half of that in suspension hepatocytes, OATP1B1 expression in SCHH was slightly higher (1.5 fold) than that found in suspension hepatocytes. The results provide support for OATP-mediated active hepatic uptake in SCHH, which indicates that SCHH could be a suitable tool for the assessment of active OATP uptake. In addition, the protein expression obtained by LC-
MS/MS measurement could be integrated into a mathematical model as a component of scaling factors for in vivo extrapolation from in vitro.
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Inhibition of active uptake in SCHH
The active component of hepatic uptake can be determined by the total hepatic uptake (PS uptake ) minus the passive diffusion (PS passive ) in an in vitro hepatocyte model.
Generally, passive diffusion in hepatocytes can be obtained by either co-incubation with an OATP inhibitor or by conducting the uptake experiment at low temperature, e. g at 4ºC.
We previously reported that the lack of uptake might be an artificial effect of a rigid cell membrane at 4ºC and the uptake in the hepatocyte model determined at 37ºC and 4ºC
might not truly reflect the functional active uptake (Kimoto et al., 2011) . Hepatic uptake and biliary excretion for compounds that are the substrates of phase I/II metabolizing enzymes or hepatic uptake transporters in SCHH
As mentioned above, rosuvastatin uptake in SCHH was nearly abolished by coincubation with 100 μΜ Rif SV. The results agree with previous reports that Rif SV (100 μM) totally blocks OATP functions in OATP transfected cell lines (Vavricka et al., 2002) .
To determine if Rif SV also affects metabolizing enzymes, biliary excretion, and active hepatic uptake by transporters other than OATPs, initial uptake and biliary excretion of various compounds were further tested in SCHH. Buprenorphine and midazolam, which are metabolized by UGT1A1 and CYP3A4, respectively, were used as compounds that penetrate the hepatocytes via passive diffusion. TC were selected as probe substrates of NTCP transporters. Rosuvastatin as a known OATP substrate was again tested in SCHH for characterizing the initial uptake and biliary excretion kinetics. In addition, rosuvastatin and taurocholate (TC) are excreted from bile through biliary efflux transporters such as multidrug resistant protein 2 (MRP2), breast cancer resistant protein (BCRP) or bile salt exporting pump (BSEP) (Ito et al., 2010) . The uptake (PS uptake and PS passive ) and biliary excretion (CL bile ) in SCHH of the compounds are shown in Figure 2 This article has not been copyedited and formatted. The final version may differ from this version. were also substantially decreased (Table 3) . Although significant increases in the intracellular concentration of buprenorphine or midazolam in SCHH were detected in the presence of Rif SV (Figure 2) , the initial uptake rates of the compounds were not significantly altered. The intracellular accumulation of buprenorphine or midazolam by
Rif SV might be due to the inhibition of CYP3A4 and UGT1A1 activities in SCHH.
Since no biliary excretion was detected for burperenophine and midazolam ( Table 4 and we conducted uptake and biliary excretion assays in SCHH to determine the in vitro active uptake (PS active ) and CL bile. To avoid potential saturation of active uptake transporters, the substrate concentrations selected either were below the OATP Km known from literature reports or lack of saturation was confirmed by our preliminary experiments. As indicated in Table 4 , initial uptake rates into SCHH for the compounds ranged from 2 to 45 uL/min/mg protein. Rif SV inhibitable active hepatic uptake ranged from 55% to 84% in SCHH for the compounds reported to undergo OATPmediated DDIs. Although the Rif SV inhibitable active uptake (%) did not correlate with the AUC changes that are observed in clinic ( Figure 3A ), these compounds were actively uptaken into hepatocyte to the extent of greater than 50% ( Figure 3A ). On the other hand, an increase of passive diffusion into hepatocytes tended to diminish the fold increase in AUC change caused by OATP inhibitors ( Figure 3B ), suggesting OATP mediated DDI risk could be low for high permeable compounds.
Discussion
Adverse clinically significant DDIs represent major challenges in drug discovery and development. In the last two decades, preclinical in vitro /in vivo models were used to This article has not been copyedited and formatted. The final version may differ from this version. effectively predict human pharmacokinetics. However, the predictions were successful for the compounds that are mainly eliminated renally or via cytochrome P-450 metabolizing enzymes (Obach, 2009) . Predicting hepatic transporter mediated clearance continues to be challenging due to large interspecies differences in hepatic transporter homology or expression, and lack of validated in vitro tools (Lai, 2009) . Hepatic drug elimination is generally composed of a series of processes that include: entrance into hepatocyte via passive diffusion and active uptake mediated by hepatic transporters; metabolic elimination through phase I and/or phase II enzymes; and excretion to bile and/or back to systemic circulation by the efflux transporters. To assess processes involved in hepatic uptake and biliary excretion for in vivo prediction, the development of an in vitro model that mimics the complexity of the hepatic transport system has become imperative.
Human hepatocyte in vitro models are widely accepted as a valuable tool for investigating drug metabolic liability and gene induction and toxicity, as well as serving as effective screening tools for NMEs. The cellular polarity that allows vectorial transport in vivo is disrupted rapidly when cells are isolated from the intact organ. Therefore, the restoration of the bile canalicular network in the cultured hepatocyte model is desired for investigating the vectorial transport of drug candidates. SCHH has been generally This article has not been copyedited and formatted. The final version may differ from this version. accepted as a good model to aid in predicting biliary clearance in humans (Bi et al., 2006) .
Following the previous efforts to understand the expression of hepatobiliary efflux transporters in SCHH , in the present study, we report, for the first time, the maintenance in SCHH of uptake hepatic transporters, OATP1B1, 1B3 and 2B1 as measured by LC-MS/MS. This provides molecular evidence to support SCHH as a model for obtaining functional hepatic uptake parameters for in vivo prediction.
Moreover, to better define the uptake clearance in SCHH, ideally an inhibitor that can block all known hepatic uptake transporters with minimum effect on passive diffusion and biliary excretion is needed. To meet these criteria, we measured rosuvastatin uptake in SCHH co-incubated with several known OATP transporter inhibitors. Under the concentrations applied, these inhibitors can completely block OATP1B1 or 1B3 activity in OATP gene overexpressing systems (Vavricka et al., 2002; Yamazaki et al., 2005; Letschert et al., 2006) . As a result, Rif SV (100 μΜ) was shown to completely knock down rosuvastatin uptake in SCHH. The inhibitor selected provided the ability in assessing the sum of active hepatic uptakes contributed by OATP transporters expressed in hepatocytes. In contrast, Rif SV (100 μΜ) had no effect on the passive diffusion of enzymes, such as UGT1A1 and CYP3A4. These inhibitory effects were minimized through optimization of experimental conditions by calculating the initial uptake rate to avoid the artificial effect on hepatic uptake caused by the inhibitory effects of Rif SV on metabolizing enzymes. Moreover, the reduced biliary excretion is observed followed the decreases of hepatic uptake. Since the intracellular accumulation of the compounds was not observed (Table 3 , 4 and Figure 2 ) with or without Ca 2+ , we speculate that the reduced biliary excretion was caused by the inhibitory effects on hepatic uptake.
However, direct inhibitory effects on hepatobiliary efflux transporters still remain to be further investigated as Rif SV appears as an inhibitor of efflux transporters including bile salt export pump (BSEP) (Wang et al., 2003) .
Three isoforms (OATP1B1, OATP1B3 and OATP2B1) are considered to play a pivotal role in the hepatic uptake of xenobiotics and endogenous compounds on the sinusoidal membrane of hepatocytes (Giacomini et al., 2010) . The OATPs transport drugs from a wide range of therapeutic classes including the 3-hydroxymethylglutaryl-CoA reductase inhibitors (statins), angiotensin II receptor antagonists (e.,g., olmesartan and valsartan), angiotensin-coverting enzyme inhibitors (enalapril and temocaprilat), the H 1 -receptor antagonist fexofenadine, and the endothelin receptor antagonist, bosentan (Giacomini et al., 2010) . As the OATP proteins are poorly conserved evolutionarily as evidenced by the lack of human orthologues in rodents, extrapolation of in vivo human from rodent models remains limited. The ITC recommends that the clinical investigation cascade should be initiated when active hepatic transport is involved in the liver clearance pathway and outlines decision trees for in vitro evaluation of hepatic uptake using a hepatocyte model to predict the potential risk of clinical DDIs. The investigation cascades are considered to be similar to the in vitro studies of drug metabolism and interaction (Giacomini et al., 2010) . As a result, developing in vitro models that can predict OATP mediated DDIs is an efficient and inexpensive approach that could reduce or eliminate the need for further clinical investigation. However, the extent of in vitro active hepatic uptake necessary to trigger the clinical assessment of DDI was not provided (Giacomini et al., 2010) . In addition, the performance of the in vitro hepatocyte models should be evaluated to increase confidence in obtaining outcomes through retrospective analysis. With this in mind, a literature review was conducted and the compounds with reported OATP-mediated clinical DDI were tested in our optimized SCHH model. As expected, active hepatic uptake of the compounds with clinically significant OATP DDIs was observed. The contribution of the active portion to overall hepatic uptake was high, being 55 to 84% of the total uptake rate. As hepatocyte lot differences in transporter expression exist, it is important that we confirmed the OATP This article has not been copyedited and formatted. The final version may differ from this version. Table 1 ).These results suggest that 50% active hepatic uptake in SCHH could be the in vitro cutoff to trigger the clinical risk assessment of hepatic transportermediated DDIs.
The relationship among solubility, passive permeability, and the effects of drug transporter and metabolizing enzymes on drug disposition has been well addressed by the biopharmaceutics drug disposition classification system (BDDCS) (Wu and Benet, 2005) .
As depicted in Figure 3B , the fold increase of AUC tended to decrease as the PSpassive in SCHH increased. The results suggest that low permeability drugs that rely primarily on transporter uptake for entry are prone to clinical DDIs mediated by OATP transporters.
When applying the classification system, transporter effects are predicted to be minimal for high permeability/high solubility Class 1 compounds (Wu and Benet, 2005) . In the gastrointestinal space, good solubility is essential for saturation of efflux transporters to obtain good absorption. Once the compounds are absorbed (into the systemic space), high permeability/low solubility Class 2 compounds could behave similarly to Class 1 compounds, in that the high permeability can overcome the transporter effects, and therefore reduce the risk of transporter mediated DDIs by competing drug entering into hepatocytes. This simple categorization under BDDCS suggests that the high vs low permeability designation reflects the differences in freedom of access to phase I and/or phase II metabolizing enzymes within hepatocytes. In addition to the factors described here, hepatic blood flow needs to be considered as under flow limited conditions the impacts of inhibition of uptake transport could be reduced.
It is interesting to note that atorvastatin is categorized as class 2 in the previous report (Wu and Benet, 2005) . However, atorvastatin was shown to be have limited diffusion into SCHH in present study, and could be categorized as a class 4 compound (9.3 uL/min/mg of atorvastatin vs. 91 ul/min/mg of propranolol, data not shown). In this regard, additional investigations are proposed to better understand the passive diffusion cutoff using cellular uptake model, e.g SCHH. Some exceptions were also found in the relationship between passive permeability and AUC increase observed in clinic. While cerivastatin was a high permeable compound in SCHH (15 μL/min/mg), a significant AUC increase (4.8 and 5.6 fold) was reported when cerivastatin was co-administered with the OATP inhibitors, CsA and gemfibrozil, respectively ( Figure 3B , circle marked).
Cerivastatin interacted with OATP proteins and is also extensively metabolized by CYP2C8 and CYP3A4 in liver via demethylation of the benzylic methyl ether moiety (Muck, 2000) . CsA and Gemfibrozil are potent inhibitors of OATP transporters, as well as inhibiting CYP metabolizing enzymes. These clinical observations could be explained by the inhibition of multi-clearance pathways resulting in a sum of effects on overall hepatic clearance. Due to lack of exposure data, it is also worthwhile to note that outliers were anticipated with co-administration of CsA, as the inhibition of OATP transporters may have been insufficient in vivo (Figure 3 below the dotline). Collectively, caution should be raised in that the interplay between transporters and metabolizing enzymes could generate a multi-level complexity in predicting clinical DDI from an in vitro system.
In conclusion, SCHH maintains hepatic transporter expression and functional activity, and appears to be a well-characterized in vitro model for prediction of in vivo human PK. Rif SV inhibited the active uptake of OATP transporters, demonstrating it was an OATP inhibitor useful to estimate the extents of active and passive uptake in SCHH. 
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